$ADAG News
Last published 2d ago
- 2d agoADAGGuggenheim 3rd Annual Healthcare Innovation Conference - ADAGENE INCEarnings Call TranscriptsGuggenheim and I'm very pleased to welcome our next presenting company Adagene and with us is Michael Chaindut, Chief Strategy Officer. Michael, thanks for joining us. Thanks for having me. So maybe just to start for tho
- 2d agoADAGGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ADAGENE INCEarnings Call TranscriptsGuggenheim and I'm very pleased to welcome our next presenting company Adagene and with us is Michael Chaindut, Chief Strategy Officer. Michael, thanks for joining us. Thanks for having me. So maybe just to start for tho
- 2d agoADAGAdagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal CancerGlobeNewswire- Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial- Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO and SUZHOU, China,
- 2w agoADAGAdagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal CancerGlobeNewswirePhase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and
- 2w agoADAGAdagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceGlobeNewswireSAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of
- 4w agoADAGAdagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual ConferenceGlobeNewswireSAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based
- 2mo agoADAGAdagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® TechnologyGlobeNewswireAmended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a
- 2mo agoADAGAdagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate CandidatesGlobeNewswireSAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of
- 2mo agoADAGAdagene to Participate in Three Upcoming Investor ConferencesGlobeNewswireSAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (NASDAQ:ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based
- 3mo agoADAGAdagene Reports Six Months 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireRandomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established
- 5mo agoADAG2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM - ADAGENE INCEarnings Call TranscriptsAll right. Good afternoon, everyone. I am Stephen Willey, one of the senior biotech analysts here at Stifel. And glad to have with us in the next session, the chief strategy officer of Atagene, Michael Shane Duke. Thanks
- 6mo agoADAGAdagene to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today
- 6mo agoADAGAdagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor TypesGlobeNewswireTriple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per
- 7mo agoADAGAdagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory BoardGlobeNewswireSAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel
- 7mo agoADAGAdagene Announces Pricing of US$70.0 Million Public Offering of ADSsGlobeNewswireSAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (NASDAQ:ADAG), a company committed to transforming the discovery and development of novel antibody-based
- 7mo agoADAGINCYAdagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)GlobeNewswirePhase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of
- 7mo agoADAGUpdated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of ResponseGlobeNewswireDose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR
- 7mo agoADAGAdagene Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireIn 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median
- 8mo agoADAGADAGENE INC. OPPENHEIMER 36TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCEADAGENE INCEarnings Call TranscriptsGood afternoon, everyone. My name is Matt Piegler. I'm an analyst here at Oppenheimer Recovery Oncology. Really excited to introduce our next company, which is Adagene. So, Mikhail, if you want to walk us through some sl
- 8mo agoADAGAdagene to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO and SUZHOU, China, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today
- 9mo agoADAGGuggenheim Emerging Outlook: Biotech Summit 2026 - ADAGENE INCEarnings Call TranscriptsAll right, so welcome everybody to the last session of the day of the Guggenheim Emerging Outlook Biotech Summit, saving the best for last, of course. My name is Paul Jang, I'm an analyst on the Gugenheim research team,
- 9mo agoADAGAdagene Provides Business Update and 2026 ObjectivesGlobeNewswireData update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated
- 11mo agoADAGAdagene Announces FDA Fast Track Designation for Muzastotug (ADG126)GlobeNewswireDesignation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc.
- 12mo agoADAGAdagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® TechnologyGlobeNewswireSAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG) and Third Arc Bio, Inc. ("Third Arc Bio"), today announced a licensing agreement under which
- 1y agoADAGAdagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal CancerGlobeNewswirePhase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with
- 1y agoADAGAdagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug ConjugateGlobeNewswireSAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the
- 1y agoADAGAdagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, ChinaGlobeNewswireSAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today
- 1y agoADAGAdagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive AdvisorGlobeNewswireSAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment
- 1y agoADAGAdagene to Participate in Two Investor Conferences in SeptemberGlobeNewswireSAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today
- 1y agoADAGAdagene Reports Six Months 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireMuzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements.
- 1y agoADAGAdagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDAGlobeNewswire- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025
- 1y agoADAGSNYAdagene announces up to $25 million strategic investment from SanofiGlobeNewswire- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July - Sanofi to exercise option on third SAFEbody di
- 1y agoADAGAdagene to Present at Jefferies Global Healthcare Conference 2025GlobeNewswireSAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that
- 1y agoADAGAdagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireCTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR)
- 1y agoADAGAdagene Appoints John Maraganore, Ph.D. as Executive AdvisorGlobeNewswire- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and
- 1y agoADAGAdagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireSAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster
- 1y agoADAGAdagene to Present at Stifel's 2025 Virtual Targeted Oncology ForumGlobeNewswireSAN DIEGO and SUZHOU, China, April 07, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that
- 1y agoADAGAdagene Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireMuzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked T cell engagers for
- 1y agoADAGAdagene to Present at 11th Annual Immuno-Oncology 360⁰ SummitGlobeNewswireSAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its
- 1y agoADAGAdagene to Present at Leerink's Global Healthcare Conference 2025GlobeNewswireSAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that
- 1y agoADAGAdagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal CancerGlobeNewswire- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) --
- 1y agoADAGAdagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers SymposiumGlobeNewswireMuzastotug (ADG126), an Anti-CTLA-4 SAFEbody® in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer Four confirmed partial responses out of twelve patients
- 1y agoADAGAdagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers SymposiumGlobeNewswireSAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will
- 1y agoADAGAdagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025GlobeNewswireSAN DIEGO and SUZHOU, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will
- 2y agoADAGAdagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingGlobeNewswire- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade - - Clinical data
- 2y agoADAGAdagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingGlobeNewswireSAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster
- 2y agoADAGAdagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)GlobeNewswire- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in
- 2y agoADAGAdagene to Participate in Investor Conferences in SeptemberGlobeNewswireSAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel
- 2y agoADAGAdagene Reports Six Month Financial Results for 2024 and Provides Corporate UpdateGlobeNewswire- Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck's anti-PD-1 therapy KEYTRUDA*
- 2y agoADAGAdagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in SeptemberGlobeNewswireSAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster